T. Hideshima

Molecular Biology · 2000–2010

A researcher in the Science corpus: 17 papers; trusts 1 researcher and is trusted by 3 researchers here, as inferred from the citation graph.

Subfields

• Molecular Biology — 45 citations into it; #9,882 of 17,773 by trust here, #2,214 by citations

Whom T. Hideshima trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. P. Richardson
2. C. Sherr
3. W. Kuehl

Who trusts T. Hideshima overall

1. J. Adams
2. P. Richardson
3. S. Rajkumar
4. A. West
5. Ricky W. Johnstone

Papers from T. Hideshima's perspective

Ordered by how strongly the researchers T. Hideshima trusts endorse each paper. Same corpus, a different order for every researcher.

1. A phase 2 study of bortezomib in relapsed, refractory myeloma. (New England Journal of Medicine)
2. Proapoptotic BAX and BAK: A Requisite Gateway to Mitochondrial Dysfunction and Death (Science)
3. The proteasome: a suitable antineoplastic target (Nature Reviews. Cancer)
4. Bax and Bak can localize to the endoplasmic reticulum to initiate apoptosis (Journal of Cell Biology)
5. Humanin peptide suppresses apoptosis by interfering with Bax activation (Nature)
6. Molecular sequelae of proteasome inhibition in human multiple myeloma cells (Proceedings of the National Academy of Sciences of the United States of America)
7. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. (Blood)
8. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. (New England Journal of Medicine)
9. International uniform response criteria for multiple myeloma (Leukemia)
10. Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1 (Nature Immunology)

Their papers

• Molecular sequelae of proteasome inhibition in human multiple myeloma cells (2002) — 787 citations
• Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets (2007) — 948 citations
• The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. (2003) — 747 citations
• Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. (2005) — 610 citations
• A phase 2 study of bortezomib in relapsed, refractory myeloma. (2003) — 2,697 citations
• Proteasome inhibition as a novel therapeutic target in human cancer. (2005) — 597 citations
• NF-κB as a Therapeutic Target in Multiple Myeloma* (2002) — 869 citations
• Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. (2003) — 602 citations
• Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. (2002) — 682 citations
• Advances in biology of multiple myeloma: clinical applications. (2004) — 638 citations
• Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. (2000) — 921 citations
• A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. (2005) — 685 citations
• Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. (2002) — 819 citations
• Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. (2010) — 873 citations
• Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. (2004) — 651 citations
• Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. (2001) — 935 citations
• The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. (2001) — 1,616 citations